| Wiesenfeld, Harold C |
SHIP-A-S01, NCT06498661: Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) |
|
|
| Recruiting | N/A | 520 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cervical Biopsy, Colposcopy, CP, Electronic Health Record Review, Endocervical Curettage, Excision, Abscission, Extirpation, Surgical Removal, HPV Self-Collection, At-home HPV Self Collection, HPV Self Collection, Human Papillomavirus Self-Collection, Human Papillomavirus Test, HPV Assay, HPV Test, Human Papillomavirus, Questionnaire Administration, Survey Administration | National Cancer Institute (NCI) | Cervical Carcinoma, Human Papillomavirus Infection | 12/24 | 03/25 | | |
NCT06611540: Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) |
|
|
| Recruiting | N/A | 500 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cervical Biopsy, Colposcopy, CP, Electronic Health Record Review, Endocervical Curettage, Excision, Abscission, Extirpation, Surgical Removal, HPV Self-Collection, At-home HPV Self Collection, HPV Self Collection, Human Papillomavirus Self-Collection, Human Papillomavirus Test, HPV Assay, HPV Test, Human Papillomavirus, Questionnaire Administration | National Cancer Institute (NCI) | Cervical Carcinoma, Human Papillomavirus Infection | 02/25 | 05/25 | | |
| Recruiting | N/A | 500 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cervical Biopsy, Colposcopy, CP, Electronic Health Record Review, Endocervical Curettage, Excision, Abscission, Extirpation, Surgical Removal, HPV Self-Collection, At-home HPV Self Collection, HPV Self Collection, Human Papillomavirus Self-Collection, Human Papillomavirus Test, HPV Assay, HPV Test, Human Papillomavirus, Questionnaire Administration, Survey Administration | National Cancer Institute (NCI) | Cervical Carcinoma, Human Papillomavirus Infection | 02/25 | 05/25 | | |
| Callaway, Clifton |
TTM-2, NCT02908308: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest |
|
|
| Completed | N/A | 1900 | Europe, US, RoW | Targeted temperature management to 33°C, Standard care with early treatment of fever | Helsingborgs Hospital, Lund University, Region Skåne - Skånevård SUND, Copenhagen Trial Unit, Center for Clinical Intervention Research, Clinical Trials Sweden, Forum South, Integrated Biobank of Luxembourg | Out-of-hospital Cardiac Arrest | 06/22 | 12/22 | | |
| Rittenberger, Jon C |
| Recruiting | N/A | 1800 | US | Therapeutic Hypothermia | University of Michigan, Johns Hopkins University, Medical University of South Carolina, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) | Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain | 07/28 | 08/28 | | |
| Doshi, Ankur |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
| Active, not recruiting | 3 | 14013 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight or Obesity, CKD, Type 2 Diabetes | 11/25 | 11/25 | | |
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms. |
|
|
| Terminated | N/A | 715 | Europe, Japan, US, RoW | THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence | Philip Morris Products S.A. | COPD, Smoking, Tobacco Use | 09/24 | 09/24 | | |
| Simon, Patsy |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
| Terminated | N/A | 1 | US | NeuraGen 3D Nerve Guide Matrix | Integra LifeSciences Corporation | Digital Nerve Injury | 07/23 | 05/24 | | |
| Active, not recruiting | N/A | 26 | US | Autologous facial fat graft injection | University of Pittsburgh | Facial Skin Texture, Facial Skin Pigmentation | 09/25 | 01/26 | | |
NCT06747715: Autologous Fresh Fat Grafting Followed by Autologous Cryopreserved Fat Grafting |
|
|
| Not yet recruiting | N/A | 22 | US | Serial Fat Grafting Fresh followed by Cryopreserved Fat | University of Pittsburgh, Armed Forces Institute of Regenerative Medicine | Facial Defect | 12/27 | 12/27 | | |
| Rubin, J Peter |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT03880656: BM-MNCs for Lower Extremity Compartment Syndrome Injury |
|
|
| Active, not recruiting | 1 | 18 | US | Intramuscular administration of autologous BM-MNCs | Oregon Health and Science University | Compartment Syndrome Traumatic Lower Extremity | 12/25 | 06/26 | | |
NCT04051242: Enhanced Bioscaffold for Volumetric Muscle Loss |
|
|
| Terminated | N/A | 10 | US | XenMatrix™ AB Surgical Graft | J. Peter Rubin, MD, United States Department of Defense | Muscle Loss | 01/24 | 01/24 | | |
NCT04440189: Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis |
|
|
| Recruiting | N/A | 124 | US | GID SVF-2 Device System | GID BIO, Inc. | Osteoarthritis, Knee | 12/23 | 12/24 | | |
| Active, not recruiting | N/A | 26 | US | Autologous facial fat graft injection | University of Pittsburgh | Facial Skin Texture, Facial Skin Pigmentation | 09/25 | 01/26 | | |
NCT06747715: Autologous Fresh Fat Grafting Followed by Autologous Cryopreserved Fat Grafting |
|
|
| Not yet recruiting | N/A | 22 | US | Serial Fat Grafting Fresh followed by Cryopreserved Fat | University of Pittsburgh, Armed Forces Institute of Regenerative Medicine | Facial Defect | 12/27 | 12/27 | | |
| Starr, Michael |
| Active, not recruiting | 3 | 514 | US | Argatroban, Eptifibatide, Placebo | Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS) | Acute Ischemic Stroke | 12/23 | 04/25 | | |
| Guyette, Francis |
| Completed | 3 | 150 | US | Sufentanil 30 MCG Sublingual Tablet, standard care pain treatment | Frank Guyette, United States Department of Defense | Traumatic Injury | 01/24 | 01/24 | | |
| Recruiting | N/A | 2009 | US | Supraglottic airway device, LMA, King, igel, Standard airway management | Jason Sperry, United States Department of Defense | Trauma Injury, Airway Control | 03/25 | 03/26 | | |
| Jadhav, Ashutosh |
| Completed | 3 | 850 | Europe, Canada, US, RoW | Placebo, Nerinetide, NA-1 | NoNO Inc., University of Calgary | Stroke, Acute | 08/23 | 08/23 | | |
| Completed | N/A | 90 | US | Thermogard XP3, Recanalization only | ZOLL Circulation, Inc., USA | Ischemic Stroke | 05/24 | 05/24 | | |
| Lewandowski, Christopher |
| Active, not recruiting | 3 | 514 | US | Argatroban, Eptifibatide, Placebo | Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS) | Acute Ischemic Stroke | 12/23 | 04/25 | | |
| Recruiting | 3 | 860 | Europe, Canada, Japan, US | Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo | Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage | 01/28 | 01/28 | | |
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial |
|
|
| Completed | 2 | 2000 | US | CAM2038, Buprenorphine Sublingual Product | Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 12/24 | 12/24 | | |
| Recruiting | N/A | 450 | US | iCOVER, Physical Presence with Reassurance | University of North Carolina, Chapel Hill, U.S. Army Medical Research Acquisition Activity | Acute Stress Reaction | 03/27 | 03/27 | | |
| Recruiting | N/A | 1094 | Canada, US | ICP + PbtO2 guided management strategy, ICP guided management strategy | University of Michigan, National Institute of Neurological Disorders and Stroke (NINDS), University of Washington, University of Pennsylvania, University of Pittsburgh, Medical University of South Carolina | Brain Injuries, Traumatic | 11/27 | 11/27 | | |
| Shirley, Eleanor |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT04051242: Enhanced Bioscaffold for Volumetric Muscle Loss |
|
|
| Terminated | N/A | 10 | US | XenMatrix™ AB Surgical Graft | J. Peter Rubin, MD, United States Department of Defense | Muscle Loss | 01/24 | 01/24 | | |
NCT04440189: Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis |
|
|
| Recruiting | N/A | 124 | US | GID SVF-2 Device System | GID BIO, Inc. | Osteoarthritis, Knee | 12/23 | 12/24 | | |
NCT06747715: Autologous Fresh Fat Grafting Followed by Autologous Cryopreserved Fat Grafting |
|
|
| Not yet recruiting | N/A | 22 | US | Serial Fat Grafting Fresh followed by Cryopreserved Fat | University of Pittsburgh, Armed Forces Institute of Regenerative Medicine | Facial Defect | 12/27 | 12/27 | | |
| Ziembicki, Jenny |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT06681194: Silver Nitrate Vs. Triamcinolone for Treatment of Hypergranulation Tissue |
|
|
| Not yet recruiting | 2/3 | 270 | US | Silver Nitrate, triamcinolone, Silver nitrate + triamcinolone | Francesco Egro | Wound Healing, Granulation Tissue | 12/28 | 12/28 | | |
| Corcos, Alain |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT06681194: Silver Nitrate Vs. Triamcinolone for Treatment of Hypergranulation Tissue |
|
|
| Not yet recruiting | 2/3 | 270 | US | Silver Nitrate, triamcinolone, Silver nitrate + triamcinolone | Francesco Egro | Wound Healing, Granulation Tissue | 12/28 | 12/28 | | |
| Elias, Garth |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT06681194: Silver Nitrate Vs. Triamcinolone for Treatment of Hypergranulation Tissue |
|
|
| Not yet recruiting | 2/3 | 270 | US | Silver Nitrate, triamcinolone, Silver nitrate + triamcinolone | Francesco Egro | Wound Healing, Granulation Tissue | 12/28 | 12/28 | | |
| Parsons, Rebecca |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
| Egro, Francesco |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT06681194: Silver Nitrate Vs. Triamcinolone for Treatment of Hypergranulation Tissue |
|
|
| Not yet recruiting | 2/3 | 270 | US | Silver Nitrate, triamcinolone, Silver nitrate + triamcinolone | Francesco Egro | Wound Healing, Granulation Tissue | 12/28 | 12/28 | | |
